National Kidney Foundation, American Society for Clinical Pathology, Leading Laboratories, and Clinical Laboratory Societies Unite to Diagnose Chronic Kidney Disease

The National Kidney Foundation (NKF), the American Society for Clinical Pathology (ASCP), and the nation’s leading laboratories and clinical laboratory societies have announced a new collaboration to remove barriers to testing for chronic kidney disease (CKD). The new collaboration will help standardize the tests used to detect CKD, improve comparison of test results between laboratories, increase early recognition of the disease, and promote patient awareness of the condition. Almost 75 million Americans are at risk for developing chronic kidney disease as a result of hypertension or diabetes. Approximately 30 million Americans have CKD, but only about 3.6 million are currently aware that they have this condition. CKD progression can be slowed or halted if the disease, which often has no symptoms, is caught in its early stages.

The collaboration is believed to be the first to combine the resources and talents of leading clinical laboratory societies, multiple laboratory providers, and a patient advocacy group to advance improvements in CKD laboratory testing. ARUP Laboratories; BioReference Laboratories, Inc.; LabCorp; Mayo Medical Laboratories; Memorial Sloan Kettering Cancer Center; Quest Diagnostics; and Sonic Healthcare, USA have aligned with the initiative recommendations to improve CKD screening, diagnosis, and care management. Any interested laboratory can join the collaboration and execute the suggested changes.

A component of this new collaboration is the recommendation of a new test profile for CKD assessment and diagnosis. This new CKD “Kidney Profile” follows evidence-based clinical practice guidelines, which recommend two tests for CKD assessment. Laboratories adopting the Kidney Profile will simplify ordering of the tests needed to detect and diagnose CKD by pairing them together under one heading on the lab requisition form or electronic health record order. Such streamlining of CKD test ordering could help to eliminate the need to search for each test separately and increases the ease of monitoring results. The Kidney Profile also makes it easier for people at risk for CKD to better understand and track their health.

“Diagnosing kidney disease early is critical to improving long-term health in patients. This was the impetus for uniting the laboratory community around solving this problem,” says Joseph Vassalotti, M.D., Chief Medical Officer, National Kidney Foundation. “The new ‘Kidney Profile’ makes it easier for primary care physicians to determine if an at-risk patient has kidney disease, as it contains all the critical tests in one easy-to-order place.”

Currently, 94% of patients with high blood pressure (hypertension) and 61% with diabetes are not receiving both tests necessary to detect and assess chronic kidney disease as recommended by clinical practice guidelines, despite these being the top two risk factors for developing chronic kidney disease.

“More than 30 million Americans are estimated to be living with CKD, but most aren’t aware of their status,” says Lee Hilborne, M.D., MPH, past president and chair of the Appropriate Test Utilization Committee, ASCP. “Once diagnosed, too many patients are in the later stages of the disease or have kidney failure, which requires dialysis or transplantation. Screening for CKD in the primary care setting may help more patients be diagnosed in early stage disease and ultimately improve outcomes.”

The new Kidney Profile combines the estimated glomerular filtration rate (eGFR), which assesses kidney function, and urine albumin-creatinine ratio (ACR), which assesses kidney damage. Both are used to test for and diagnose CKD in primary care settings. Specifically, the Kidney Profile combines: 1) eGFR (serum creatinine with eGFR: CPT 82565) and 2) urine ACR (albumin, urine [e.g., microalbumin], quantitative: CPT 82043 plus urine creatinine: CPT 82570). People living with CKD have an elevated risk for cardiovascular disease. This combination of eGFR and ACR testing has been shown to be a strong predictor of both cardiovascular mortality and kidney failure risk.

NKF and ASCP also recommend that laboratories use the same equation to estimate GFR and rename the microalbumin test to one that more accurately reflects what it is measuringalbumin-creatinine ratio, urine. Standardized ACR reporting using milligrams per gram will make it easier for clinicians to compare results received from different labs.

Health care professionals can learn more about the CKD Kidney Profile by visiting A fact sheet for dotors to share with their patients is available. This brochure explains what kidneys do, how to keep kidneys healthy, and what tests determine if kidneys are working properly.

Gina Chiri-Osmond

Gina Chiri-Osmond is a Marketing Channel Manager at Mayo Clinic Laboratories.